pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

199 catalysts · 51 phase 2 completion · 35 phase 1 completion · 23 phase 2 initiation · 22 phase 1 2 completion · 18 phase 1 initiation · 13 phase 1 2 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: dlbcl×TA: ophthalmology×TA: oncology×TA: immunology×clear all
type
  • phase 2 completion51
  • phase 1 completion35
  • phase 2 initiation23
  • phase 1 2 completion22
  • phase 1 initiation18
  • phase 1 2 initiation13
  • phase 3 initiation7
  • phase 0 trial completion6
  • filing5
  • phase 3 completion4
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 20, 2026

    40
    ›Apr 24, 2026patent expiry90d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026drug expiry90d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026phase 1 completion90d agoAkeso Inc — AK-132 (Phase I Trial Completion)AK-132

    Therapy area: Oncology. Indication: Solid Tumor

    full page →AK-132 →source: globaldata
    ›Apr 24, 2026phase 1 initiation90d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

    Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

    full page →CMSD-001 →source: globaldata
    ›Apr 24, 2026phase 1 results90d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

    Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

    full page →viral-specific T-cells →source: globaldata
    ›Apr 24, 2026phase 1 2 initiation90d agoMayo Clinic — eflornithine hydrochloride (Phase I/II Trial Initiation)eflornithine hydrochloride

    Therapy area: Oncology. Indication: Anaplastic Astrocytoma, Glioblastoma Multiforme (GBM), High-Grade Glioma, Low-Grade Astrocytoma, Malignant Glioma, Oligodendroglioma

    full page →eflornithine hydrochloride →source: globaldata
    ›Apr 24, 2026phase 2 completion90d agoUniversity Health Network — bevacizumab (Phase II Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

    full page →bevacizumab →source: globaldata
    ›Apr 24, 2026phase 2 completion90d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

    Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

    full page →lixudebart →source: globaldata
    ›Apr 24, 2026phase 2 completion90d agoJapanese Governmental Office — capecitabine (Phase II Trial Completion)capecitabine

    Therapy area: Oncology. Indication: Rectal Cancer

    full page →capecitabine →source: globaldata
    ›Apr 24, 2026phase 2 results90d agoCity of Hope — Methotrexate Teva (Phase II Trial Results)Maxtrex

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)

    full page →Maxtrex →source: globaldata
    ›Apr 24, 2026phase 3 completion90d agoImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd — timdarpacept (Phase III Trial Completion)timdarpacept

    Therapy area: Oncology. Indication: Chronic Myelomonocytic Leukemia (CMML)

    full page →timdarpacept →source: globaldata
    ›Apr 24, 2026phase iv trial initiation90d agoAll India Institute of Medical Sciences Jodhpur — melatonin (Phase IV Trial Initiation)melatonin

    Therapy area: Central Nervous System, Immunology. Indication: Delirium, Inflammation

    full page →melatonin →source: globaldata
    ›Apr 24, 2026phase iv trial initiation90d agoDr Rajendra Prasad Centre for Ophthalmic Sciences — carboxymethylcellulose (Phase IV Trial Initiation)carboxymethylcellulose

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

    full page →carboxymethylcellulose →source: globaldata
    ›Apr 25, 2026constraining patent expiry europe89d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Europe))SL-901

    Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

    full page →SL-901 →source: globaldata
    ›Apr 25, 2026patent expiry89d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Japan))SL-901

    Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

    full page →SL-901 →source: globaldata
    ›Apr 25, 2026phase 0 trial completion89d agoExegenesis Bio Inc — EXG-202 (Phase 0 Trial Completion)EXG-202

    Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Macular Degeneration, Wet (Neovascular / Exudative) Macular Degeneration

    full page →EXG-202 →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoHenan Cancer Hospital — GH-2616 (Phase I Trial Completion)GH-2616

    Therapy area: Oncology. Indication: Lung Adenocarcinoma, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Solid Tumor, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Uterine Cancer

    full page →GH-2616 →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoBristar Immunotech Biotechnology Co Ltd — YTS-109 (Phase I Trial Completion)YTS-109

    Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia

    full page →YTS-109 →source: globaldata
    ›Apr 25, 2026phase 1 2 completion89d agoGeneral Hospital of the People's Liberation Army — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Nodal Marginal Zone B-Cell Lymphoma, Non-Hodgkin Lymphoma, Primary Mediastinal B-Cell Lymphoma, Splenic Marginal Zone B-Cell Lymphoma

    full page →cyclophosphamide →source: globaldata
    ›Apr 25, 2026phase 1 2 completion89d agoShanghai YaKe Biotechnology Co Ltd — CD7 CAR-T Cells (Phase I/II Trial Completion)CD7 CAR-T Cells

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia

    full page →CD7 CAR-T Cells →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoTianjin Medical University Cancer Institute and Hospital — fluorouracil (Phase II Trial Completion)Efudex

    Therapy area: Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma)

    full page →Efudex →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoTehran University of Medical Sciences — FOLFOX [leucovorin + fluorouracil + oxaliplatin] (Phase II Trial Completion)FOLFOX [leucovorin + fluorouracil + oxaliplatin]

    Therapy area: Oncology. Indication: Rectal Cancer

    full page →FOLFOX [leucovorin + fluorouracil + oxaliplatin] →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)blinatumomab

    Therapy area: Oncology. Indication: B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

    full page →blinatumomab →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoEmami Ltd — Himani fast relief gel (Phase II Trial Completion)Himani fast relief gel

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders. Indication: Inflammation, Myalgia (Muscle Pain), Unspecified Musculoskeletal Disorders

    full page →Himani fast relief gel →source: globaldata
    ›Apr 25, 2026phase 2 initiation89d agoAffiliated Hospital of North Sichuan Medical College — Radioactive Iodine Therapy (Phase II Trial Initiation)Radioactive Iodine Therapy

    Therapy area: Oncology. Indication: Follicular Thyroid Cancer, Papillary Thyroid Cancer, Thyroid Cancer

    full page →Radioactive Iodine Therapy →source: globaldata
    ›Apr 25, 2026phase 2 initiation89d agoKIMS Hospital — bifidobacterium (Phase II Trial Initiation)bifidobacterium

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →bifidobacterium →source: globaldata
    ›Apr 25, 2026phase 2 initiation89d agoShanghai Henlius Biotech Inc — HLX-43 (Phase II Trial Initiation)HLX-43

    Therapy area: Oncology. Indication: Breast Cancer, Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

    full page →HLX-43 →source: globaldata
    ›Apr 25, 2026phase 2 initiation89d agoJazz Pharmaceuticals Plc — durvalumab (Phase II Trial Initiation)durvalumab

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →durvalumab →source: globaldata
    ›Apr 25, 2026phase 2 initiation89d agoNovartis AG — asciminib hydrochloride (Phase II Trial Initiation)asciminib hydrochloride

    Therapy area: Oncology. Indication: Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

    full page →asciminib hydrochloride →source: globaldata
    ›Apr 25, 2026phase 3 initiation89d agoDr. Reddy's Laboratories Ltd — olokizumab (Phase III Trial Initiation)olokizumab

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →olokizumab →source: globaldata
    ›Apr 26, 2026phase 1 completion88d agoPfizer Inc — PF-08046032 (Phase I Trial Completion)PF-08046032

    Therapy area: Oncology. Indication: Advanced Malignancy, Diffuse Large B-Cell Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Solid Tumor

    full page →PF-08046032 →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoUniversity Health Network — decidual stromal cells (Phase II Trial Completion)decidual stromal cells

    Therapy area: Immunology. Indication: Graft Versus Host Disease (GVHD)

    full page →decidual stromal cells →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoCentral Council for Research in Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Ophthalmology. Indication: Asthenopia (Eye Strain), Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

    full page →unani medicine →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoAnyang Tumor Hospital — camrelizumab (Phase II Trial Completion)apatinib mesylate

    Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

    full page →apatinib mesylate →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoMemorial Sloan Kettering Cancer Center — iberdomide hydrochloride (Phase II Trial Completion)iberdomide hydrochloride

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease)

    full page →iberdomide hydrochloride →source: globaldata
    ›Apr 26, 2026phase 2 initiation88d agoBeijing Chao-Yang Hospital — oxymetazoline hydrochloride (Phase II Trial Initiation)oxymetazoline hydrochloride

    Therapy area: Ophthalmology. Indication: Blepharitis, Ptosis

    full page →oxymetazoline hydrochloride →source: globaldata
    ›Apr 26, 2026phase 2 initiation88d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

    full page →DICLOFENAC SODIUM →source: globaldata
    ›Apr 26, 2026phase 2 initiation88d agoBeijing StarMab BioMed Technology Ltd — SM-3321 (Phase II Trial Initiation)SM-3321

    Therapy area: Oncology. Indication: Advanced Malignancy, Solid Tumor

    full page →SM-3321 →source: globaldata
    ›Apr 26, 2026phase 2 results88d agoAllogene Therapeutics Inc — ALLO-647 (Phase II Trial Results)ALLO-647

    Therapy area: Oncology. Indication: Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma

    full page →ALLO-647 →source: globaldata
    ›Apr 26, 2026phase 3 initiation88d agoStanford University — zanubrutinib (Phase III Trial Initiation)zanubrutinib

    Therapy area: Immunology. Indication: Immunoglobulin G4-Related Disease (IgG4-RD)

    full page →zanubrutinib →source: globaldata

    Week of Apr 27, 2026

    10
    ›Apr 27, 2026phase 1 completion87d agoCTI Clinical Trial and Consulting Services Australia Pty Ltd — PTC-844 (Phase I Trial Completion)PTC-844

    Therapy area: Immunology. Indication: Unspecified Immunological Disorders

    full page →PTC-844 →source: globaldata
    ›Apr 27, 2026phase 1 completion
    ← prev
    page 1 of 4
    next →
    87d ago
    Fortrea Holdings Inc — balinatunfib (Phase I Trial Completion)balinatunfib

    Therapy area: Gastrointestinal, Immunology. Indication: Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Ulcerative Colitis

    full page →balinatunfib →source: globaldata
    ›Apr 27, 2026phase 1 initiation87d agoNational Heart Lung and Blood Institute — fostamatinib (Phase I Trial Initiation)fostamatinib

    Therapy area: Immunology. Indication: Liver Transplant Rejection

    full page →fostamatinib →source: globaldata
    ›Apr 27, 2026phase 1 initiation87d agoCity of Hope — CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] (Phase I Trial Initiation)CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone]

    Therapy area: Oncology. Indication: Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Follicular Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), T-Cell Lymphomas

    full page →CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] →source: globaldata
    ›Apr 27, 2026phase 1 initiation87d agoNational Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)Autologous B7-H3 CAR T

    Therapy area: Oncology. Indication: Neuroendocrine Cancer, Small-Cell Lung Cancer, Solid Tumor

    full page →Autologous B7-H3 CAR T →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation87d agoNational Institutes of Health Clinical Center — azacitidine (Phase I/II Trial Initiation)Onureg

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

    full page →Onureg →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation87d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — EBTATE (Phase I/II Trial Initiation)EBTATE

    Therapy area: Oncology. Indication: Thyroid Cancer

    full page →EBTATE →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation87d agoNational Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)sacituzumab govitecan

    Therapy area: Oncology. Indication: Neuroendocrine Cancer, Neuroendocrine Carcinoma, Small-Cell Lung Cancer

    full page →sacituzumab govitecan →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoSMBT Ayurved College and Hospital — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →ayurvedic medicine →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoPt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)nivolumab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer

    full page →nivolumab →source: globaldata
    $ALLO1.8636+0.74%
    $NVS153.87+2.88%
    $PFE25.05+0.44%
    $JAZZ254.22+4.42%
    $FTRE18.05+0.78%